Nancy Wainman

1.1k total citations
26 papers, 944 citations indexed

About

Nancy Wainman is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Nancy Wainman has authored 26 papers receiving a total of 944 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 15 papers in Oncology and 7 papers in Genetics. Recurrent topics in Nancy Wainman's work include Cancer therapeutics and mechanisms (6 papers), Glioma Diagnosis and Treatment (5 papers) and Cancer Treatment and Pharmacology (5 papers). Nancy Wainman is often cited by papers focused on Cancer therapeutics and mechanisms (6 papers), Glioma Diagnosis and Treatment (5 papers) and Cancer Treatment and Pharmacology (5 papers). Nancy Wainman collaborates with scholars based in Canada, United States and United Kingdom. Nancy Wainman's co-authors include Elizabeth A. Eisenhauer, Karl Bélanger, Reinhard Lohmann, Gregory K. Reid, David J. Stewart, Lesley Seymour, Ajit Shah, D. Scott Ernst, Peter Forsyth and Richard Tozer and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Nancy Wainman

26 papers receiving 918 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nancy Wainman Canada	18	686	296	166	149	139	26	944
David E. MacCallum United Kingdom	11	739 1.1×	472 1.6×	181 1.1×	96 0.6×	102 0.7×	21	1.1k
Jean Melville United Kingdom	5	497 0.7×	373 1.3×	129 0.8×	73 0.5×	124 0.9×	10	768
Rachel V. Pearline United States	5	756 1.1×	343 1.2×	84 0.5×	103 0.7×	135 1.0×	7	976
Ruzanna Atoyan United States	14	772 1.1×	241 0.8×	155 0.9×	56 0.4×	69 0.5×	21	1.1k
Aidan G. Gilmartin United States	12	902 1.3×	544 1.8×	244 1.5×	68 0.5×	110 0.8×	28	1.2k
Roderick P. Regala United States	9	706 1.0×	328 1.1×	172 1.0×	41 0.3×	94 0.7×	10	932
Nicole E. Carlson United States	9	816 1.2×	319 1.1×	97 0.6×	96 0.6×	78 0.6×	10	1.0k
Amit J. Sabnis United States	13	562 0.8×	245 0.8×	105 0.6×	86 0.6×	125 0.9×	32	951
Sara Volorio Italy	13	900 1.3×	272 0.9×	62 0.4×	104 0.7×	81 0.6×	26	1.1k
Yuanyan Wei China	20	657 1.0×	373 1.3×	115 0.7×	79 0.5×	56 0.4×	35	949

Countries citing papers authored by Nancy Wainman

Since Specialization

Citations

This map shows the geographic impact of Nancy Wainman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Wainman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Wainman more than expected).

Fields of papers citing papers by Nancy Wainman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Wainman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Wainman. The network helps show where Nancy Wainman may publish in the future.

Co-authorship network of co-authors of Nancy Wainman

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy Wainman. A scholar is included among the top collaborators of Nancy Wainman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy Wainman. Nancy Wainman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Knox, Jennifer J., Sharlene Gill, Timothy W. Synold, et al.. (2008). A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Investigational New Drugs. 26(3). 265–272. 55 indexed citations

Lee, Christopher W., Karl Bélanger, Sanjay C. Rao, et al.. (2007). A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Investigational New Drugs. 26(3). 249–255. 83 indexed citations

Winquist, Eric, Jennifer J. Knox, Jean-Pierre M. Ayoub, et al.. (2006). Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Investigational New Drugs. 24(2). 159–167. 105 indexed citations

Wong, Ralph, Tara Baetz, Marianne Krahn, et al.. (2006). SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 24(4). 347–351. 1 indexed citations

Ernst, D. Scott, Elizabeth A. Eisenhauer, Nancy Wainman, et al.. (2005). Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma. Investigational New Drugs. 23(6). 569–575. 89 indexed citations

Webster, Marc, Gregory Cairncross, S. Gertler, et al.. (2005). Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea. Investigational New Drugs. 23(6). 591–596. 5 indexed citations

Le, Lyly, Charles Erlichman, Jake J. Thiessen, et al.. (2004). Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days. Investigational New Drugs. 22(2). 159–167. 33 indexed citations

Burdette-Radoux, Susan, Richard Tozer, Reinhard Lohmann, et al.. (2004). Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Investigational New Drugs. 22(3). 315–322. 72 indexed citations

Bélanger, Karl, David R. Macdonald, Gregory Cairncross, et al.. (2003). A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Investigational New Drugs. 21(4). 473–480. 3 indexed citations

10.

Davis, Alison, Karen A. Gelmon, Lillian L. Siu, et al.. (2003). Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks. Investigational New Drugs. 21(1). 85–97. 78 indexed citations

11.

Stewart, David J., Ross C. Donehower, Elizabeth A. Eisenhauer, et al.. (2003). A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Annals of Oncology. 14(5). 766–774. 77 indexed citations

12.

Tozer, Richard, Susan Burdette-Radoux, M. L. Davis, et al.. (2002). A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma – A National Cancer Institute of Canada Clinical Trials Group Study. Investigational New Drugs. 20(4). 407–412. 18 indexed citations

13.

Quirt, Ian, A. Bodurtha, Reinhard Lohmann, et al.. (2002). Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 20(4). 431–437. 35 indexed citations

14.

Bélanger, Karl, Malcolm J. Moore, Sharyn D. Baker, et al.. (2002). Phase I and Pharmacokinetic Study of Novel l-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days. Journal of Clinical Oncology. 20(10). 2567–2574. 19 indexed citations

15.

Gertler, S., David Macdonald, Michael Goodyear, et al.. (2000). NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Annals of Oncology. 11(3). 315–318. 30 indexed citations

16.

Bélanger, K., Richard Tozer, Susan Burdette-Radoux, et al.. (1999). Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule. European Journal of Cancer. 35. S374–S374. 2 indexed citations

17.

Siu, Lillian L., Amit M. Oza, E. Eisenhauer, et al.. (1998). Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.. Journal of Clinical Oncology. 16(3). 1122–1130. 25 indexed citations

18.

Forsyth, Peter, et al.. (1996). Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 14(2). 203–206. 42 indexed citations

19.

Macdonald, David, David J. Stewart, Peter Forsyth, et al.. (1996). Phase II study of topotecan in patients with recurrent malignant glioma. Annals of Oncology. 7(2). 205–207. 61 indexed citations

20.

Bélanger, Karl, Jacques Jolivet, Jean A. Maroun, et al.. (1993). Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole. Investigational New Drugs. 11(4). 301–308. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact